tiprankstipranks
Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
US Market
NMRA
Neumora Therapeutics, Inc.
RESEARCH TOOLSreports
Want to see NMRA full AI Analyst Report?

Neumora Therapeutics, Inc. (NMRA) Stock Forecast & Price Target

431 Followers
See the Price Targets and Ratings of:

NMRA Analyst Ratings

Moderate Buy
8Ratings
Moderate Buy
6 Buy
1 Hold
1 Sell
Based on 8 analysts giving stock ratings to
Neumora
Therapeutics, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NMRA Stock 12 Month Forecast

Average Price Target

$6.33
▲(325.06% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Neumora Therapeutics, Inc. in the last 3 months. The average price target is $6.33 with a high forecast of $14.00 and a low forecast of $3.00. The average price target represents a 325.06% change from the last price of $1.49.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","7":"$7","11":"$11","15":"$15","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.333333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,3,7,11,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.62,2.5723076923076924,3.5246153846153847,4.476923076923077,5.429230769230768,6.381538461538461,7.333846153846153,8.286153846153844,9.238461538461538,10.19076923076923,11.143076923076922,12.095384615384614,13.047692307692305,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.62,1.9825641025641025,2.345128205128205,2.707692307692308,3.0702564102564103,3.4328205128205127,3.7953846153846156,4.1579487179487185,4.52051282051282,4.883076923076922,5.245641025641025,5.608205128205128,5.970769230769231,{"y":6.333333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.62,1.7261538461538461,1.8323076923076924,1.9384615384615385,2.0446153846153847,2.1507692307692308,2.256923076923077,2.363076923076923,2.4692307692307693,2.5753846153846154,2.6815384615384614,2.787692307692308,2.8938461538461535,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.78,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.02,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.09,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$14.00Average Price Target$6.33Lowest Price Target$3.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on NMRA
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$7
Buy
369.80%
Upside
Reiterated
07/28/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Vericel (NASDAQ: VCEL), Sarepta Therapeutics (NASDAQ: SRPT) and Neumora Therapeutics, Inc. (NASDAQ: NMRA)
Needham Analyst forecast on NMRA
Ami Fadia
Needham
Needham
$5
Buy
235.57%
Upside
Reiterated
07/27/26
Neumora Maintained at Buy as NMRA-215 Advances Toward Phase 1; $5 Price Target Reaffirmed
William Blair Analyst forecast on NMRA
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
07/27/26
Neumora Therapeutics: Buy Rating Backed by De-Risked NMRA-215 Development and Strengthening NLRP3 Class Thesis
RBC Capital Analyst forecast on NMRA
Brian Abrahams
RBC Capital
RBC Capital
$7→$5
Buy
235.57%
Upside
Reiterated
07/13/26
Neumora Therapeutics price target lowered to $5 from $7 at RBC CapitalNeumora Therapeutics price target lowered to $5 from $7 at RBC Capital
Mizuho Securities Analyst forecast on NMRA
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$4
Buy
168.46%
Upside
Reiterated
06/21/26
Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (NYSE MKT: PTHS), Neumora Therapeutics, Inc. (NASDAQ: NMRA) and Amgen (NASDAQ: AMGN)
J.P. Morgan Analyst forecast on NMRA
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Sell
―
Reiterated
05/26/26
Analysts Conflicted on These Healthcare Names: CVS Health (NYSE: CVS), Revolution Medicines (NASDAQ: RVMD) and Neumora Therapeutics, Inc. (NASDAQ: NMRA)
Stifel Nicolaus Analyst forecast on NMRA
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$3
Hold
101.34%
Upside
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NASDAQ: NMRA), Biomea Fusion (NASDAQ: BMEA) and Adaptive Biotechnologies (NASDAQ: ADPT)
Guggenheim Analyst forecast on NMRA
Yatin Suneja
Guggenheim
Guggenheim
$14
Buy
839.60%
Upside
Reiterated
05/07/26
Neumora Therapeutics, Inc. (NMRA) Gets a Buy from Guggenheim
Leerink Partners Analyst forecast on NMRA
Marc Goodman
Leerink Partners
Leerink Partners
$8
Buy
436.91%
Upside
Initiated
01/11/26
Diversified CNS Pipeline and NLRP3 Opportunity Drive Upside in Neumora: Justifying an Outperform/Buy Rating
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on NMRA
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$7
Buy
369.80%
Upside
Reiterated
07/28/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Vericel (NASDAQ: VCEL), Sarepta Therapeutics (NASDAQ: SRPT) and Neumora Therapeutics, Inc. (NASDAQ: NMRA)
Needham Analyst forecast on NMRA
Ami Fadia
Needham
Needham
$5
Buy
235.57%
Upside
Reiterated
07/27/26
Neumora Maintained at Buy as NMRA-215 Advances Toward Phase 1; $5 Price Target Reaffirmed
William Blair Analyst forecast on NMRA
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
07/27/26
Neumora Therapeutics: Buy Rating Backed by De-Risked NMRA-215 Development and Strengthening NLRP3 Class Thesis
RBC Capital Analyst forecast on NMRA
Brian Abrahams
RBC Capital
RBC Capital
$7→$5
Buy
235.57%
Upside
Reiterated
07/13/26
Neumora Therapeutics price target lowered to $5 from $7 at RBC CapitalNeumora Therapeutics price target lowered to $5 from $7 at RBC Capital
Mizuho Securities Analyst forecast on NMRA
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$4
Buy
168.46%
Upside
Reiterated
06/21/26
Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (NYSE MKT: PTHS), Neumora Therapeutics, Inc. (NASDAQ: NMRA) and Amgen (NASDAQ: AMGN)
J.P. Morgan Analyst forecast on NMRA
Tessa Romero
J.P. Morgan
J.P. Morgan
―
Sell
―
Reiterated
05/26/26
Analysts Conflicted on These Healthcare Names: CVS Health (NYSE: CVS), Revolution Medicines (NASDAQ: RVMD) and Neumora Therapeutics, Inc. (NASDAQ: NMRA)
Stifel Nicolaus Analyst forecast on NMRA
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$3
Hold
101.34%
Upside
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NASDAQ: NMRA), Biomea Fusion (NASDAQ: BMEA) and Adaptive Biotechnologies (NASDAQ: ADPT)
Guggenheim Analyst forecast on NMRA
Yatin Suneja
Guggenheim
Guggenheim
$14
Buy
839.60%
Upside
Reiterated
05/07/26
Neumora Therapeutics, Inc. (NMRA) Gets a Buy from Guggenheim
Leerink Partners Analyst forecast on NMRA
Marc Goodman
Leerink Partners
Leerink Partners
$8
Buy
436.91%
Upside
Initiated
01/11/26
Diversified CNS Pipeline and NLRP3 Opportunity Drive Upside in Neumora: Justifying an Outperform/Buy Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neumora Therapeutics, Inc.

3 Months
Brian AbrahamsRBC Capital
Success Rate
7/13 ratings generated profit
54%
Average Return
-5.36%
Copying Brian Abrahams's trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of -5.36% per trade.
1 Year
Douglas TsaoH.C. Wainwright
Success Rate
8/19 ratings generated profit
42%
Average Return
+10.78%
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 42.11% of your transactions generating a profit, with an average return of +10.78% per trade.
2 Years
Douglas TsaoH.C. Wainwright
Success Rate
7/19 ratings generated profit
37%
Average Return
-4.71%
Copying Douglas Tsao's trades and holding each position for 2 Years would result in 36.84% of your transactions generating a profit, with an average return of -4.71% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NMRA Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
13
11
14
15
15
Buy
2
2
2
2
3
Hold
2
1
2
2
1
Sell
1
0
1
1
1
Strong Sell
0
0
0
0
0
total
18
14
19
20
20
In the current month, NMRA has received 18 Buy Ratings, 1 Hold Ratings, and 1 Sell Ratings. NMRA average Analyst price target in the past 3 months is 6.33.
Each month's total comprises the sum of three months' worth of ratings.

NMRA Financial Forecast

NMRA Earnings Forecast

Next quarter’s earnings estimate for NMRA is -$0.24 with a range of -$0.30 to -$0.20. The previous quarter’s EPS was -$0.30. NMRA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 45.99% of the time in the same period. In the last calendar year NMRA has Performed in-line its overall industry.
Next quarter’s earnings estimate for NMRA is -$0.24 with a range of -$0.30 to -$0.20. The previous quarter’s EPS was -$0.30. NMRA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 45.99% of the time in the same period. In the last calendar year NMRA has Performed in-line its overall industry.
No data currently available

NMRA Sales Forecast

Next quarter’s sales forecast for NMRA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. NMRA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 29.50% of the time in the same period. In the last calendar year NMRA has Performed in-line its overall industry.
Next quarter’s sales forecast for NMRA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. NMRA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 29.50% of the time in the same period. In the last calendar year NMRA has Performed in-line its overall industry.

NMRA Stock Forecast FAQ

What is NMRA’s average 12-month price target, according to analysts?
Based on analyst ratings, Neumora Therapeutics, Inc.’s 12-month average price target is 6.33.
    What is NMRA’s upside potential, based on the analysts’ average price target?
    Neumora Therapeutics, Inc. has 325.06% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NMRA a Buy, Sell or Hold?
          Neumora Therapeutics, Inc. has a consensus rating of Moderate Buy which is based on 6 buy ratings, 1 hold ratings and 1 sell ratings.
            What is Neumora Therapeutics, Inc.’s price target?
            The average price target for Neumora Therapeutics, Inc. is 6.33. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $14.00 ,the lowest forecast is $3.00. The average price target represents 325.06% Increase from the current price of $1.49.
              What do analysts say about Neumora Therapeutics, Inc.?
              Neumora Therapeutics, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of NMRA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.